Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798939 | 1.00 | KDM2B (0.41) | KDM2BDPP4HRH3SIGMAR1 | |
| SCHEMBL19808717 | 1.00 | KDM2B (0.41) | KDM2BDPP4HRH3SIGMAR1 | |
| SCHEMBL19798937 | 1.00 | KDM2B (0.41) | KDM2BDPP4HRH3SIGMAR1 | |
| SCHEMBL19798918 | 1.00 | KDM2B (0.41) | KDM2BDPP4HRH3SIGMAR1 | |
| SCHEMBL19798924 | 1.00 | KDM2B (0.41) | KDM2BDPP4HRH3SIGMAR1 | |
| SCHEMBL19798925 | 1.00 | KDM2B (0.41) | KDM2BDPP4HRH3SIGMAR1 | |
| SCHEMBL19799021 | 0.84 | KDM2B (0.40) | KDM2BDPP4 | |
| SCHEMBL19799032 | 0.84 | KDM2B (0.40) | KDM2BDPP4 | |
| SCHEMBL21120576 | 0.84 | KDM2B (0.40) | KDM2BDPP4 | |
| SCHEMBL19799033 | 0.84 | KDM2B (0.40) | KDM2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | KDM2B 3/4885DPP4 1273/4885HRH3 376/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | KDM2B 3/4885DPP4 1273/4885HRH3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.